New US FDA draft guidance on bioanalytical method validation versus current FDA and EMA guidelines: chromatographic methods and ISR

References

• 1  van Amsterdam P, Companjen A, Brudny-Kloeppel M et al. The European Bioanalysis Forum community’s evaluation, interpretation and implementation of the European Medicines Agency guideline on Bioanalytical Method Validation. Bioanalysis5(6),645–659 (2013).Link, CAS, Google Scholar
• 2  Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J.9(1),E30–E42 (2007).Crossref, Google Scholar
• 3  Fast DM, Kelley M, Viswanathan C et al. AAPS workshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples – implications of crystal city recommendations. AAPS J.11(2),238–241 (2009).Crossref, Medline, Google Scholar
• 4  Sennbro CJ, Knutsson M, van Amsterdam P, Timmerman P. Anticoagulant counter ion impact on bioanalytical LC–MS/MS assays: results from discussions and experiments within the European Bioanalysis Forum. Bioanalysis3(21),2393–2399 (2011).Link, CAS, Google Scholar
• 5  Bergeron A, Bergeron M, Garofolo F. Confirmation of no impact from different anticoagulant counter ions on bioanalytical method. Bioanalysis4(8),897–908 (2012).Link, CAS, Google Scholar
• 6  Freisleben A, Brudny- Klöppel M, Mulder H et al. Blood stability testing: European Bioanalysis Forum view on current challenges for regulated bioanalysis. Bioanalysis3(12),1333–1336 (2011).Link, CAS, Google Scholar
• 7  Heinig K, Zwanziger E, Zimmer D. What are the challenges of stability investigations and sample stabilization in regulated bioanalysis? Bioanalysis5(15),1811–1814 (2013).Link, CAS, Google Scholar
• 8  Timmerman P, Kall MA, Gordon B. Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum. Bioanalysis2(7),1185–1194 (2010).Link, Google Scholar
• 101  US FDA. Guidance for Industry: Bioanalytical Method Validation (2013). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM368107.pdfGoogle Scholar
• 102  US FDA. Guidance for Industry: Bioanalytical Method Validation (2001). www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070107.pdfGoogle Scholar
• 103  European Medicines Agency. Guideline on bioanalytical method validation (July 2011). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdfGoogle Scholar
• 104  Reflection Paper for Laboratories That Perform the Analysis or Evaluation of Clinical Trial Samples. www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2010/09/WC500096987.pdfGoogle Scholar
• 105  Global Bioanalysis Consortium: Team A2 – Tiered Approaches to Method Validation. www.globalbioanalysisconsortium.org/site/gbc/assets/documents/HT%20slide%20decks/GBC%20Team%20A-2%20for%20upload.pdfGoogle Scholar